MET and cancer: The HGF/c-Met pathway has been implicated in invasion and metastasis in HNSCC and other cancers, both in vitro and in vivo [27-31] and has been linked to resistance of EGFR inhibitors and cisplatin [20,32-35], making both c-Met and HGF attractive drug targets as well as determinants of treatment.